Ausam Biotech to Ink Licensing Deal for Proteomic-Based Diagnostic

Oct 03, 2001

WASHINGTON, DC, Oct. 3 – Ausam Biotechnologies is set to strike a licensing deal in the current quarter with a pair of "major US pharmaceutical companies" for its proteomic-based kidney disease diagnostic, the company’s CEO told GenomeWeb on Wednesday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu